GLP-3 RT
Metabolic Research Peptide
Size: 5mg
With code BOGO
GLP-3 RT is a single-molecule triple agonist of the GLP-1, GIP, and glucagon receptors, studied for metabolic regulation, appetite signaling, and energy balance in research models.
GLP-3 RT
Triple receptor peptide that targets GLP-1, GIP, and glucagon pathways
Studied for metabolic-regulation signaling in research models
Investigated for appetite-signaling and energy-balance pathways
Long-acting profile in research settings
Typically referenced in once-weekly research protocols
Research Use Notes
Supplied as lyophilized powder
Requires reconstitution before use
Research Water required for mixing (sold separately)
Swirl gently, never shake
Storage
Store lyophilized powder vial in freezer
Keep at 2 to 8°C
Protect from light and heat
After mixing, keep refrigerated
Use within typical research handling window after reconstitution
Handling
Use sterile technique during reconstitution
For laboratory research use only
Certificate of Analysis
Independently 8x Tested by Kovera Labs and/or ILS Labs
(Click here to learn about 8x testing)
All certificates are issued by independent ISO-accredited laboratories. Lot-specific documents are made available to qualified research professionals on request.
Frequently Bought Together
Commonly paired to support consistent, reliable experimentation.
Cagrilintide
$90$45per vialWith code BOGOMetabolic Research Peptide
BPC-157
$75$37.50per vialWith code BOGOTissue Repair Peptide
Compound Information
Technical specifications
What Is GLP-3 RT?
LY3437943 · GIP / GLP-1 / glucagon triple agonist
- Type
- Synthetic peptide
- CAS Number
- 2381089-83-2
- Molecular Weight
- 4,731 g/mol
- Amino Acids
- 39
- Fatty Acid Chain
- C20 diacid
Stability Information
-20°C
24+ months
2-8°C
~30 days
Sources & References
Peer-reviewed research
Triple–Hormone-Receptor Agonist GLP-3 RT for Obesity — A Phase 2 Trial
2023 · DOI: 10.1056/NEJMoa2301972 · Jastreboff AM, et al.
View SourceThe LancetGLP-3 RT for People with Type 2 Diabetes — A Phase 2 Trial
2023 · DOI: 10.1016/S0140-6736(23)01053-X · Rosenstock J, et al.
View SourceNature MedicineGLP-3 RT for Metabolic Dysfunction-Associated Steatotic Liver Disease
2024 · DOI: 10.1038/s41591-024-03018-2 · Sanyal AJ, et al.
View SourceLancet Diabetes & EndocrinologyEffects of GLP-3 RT on Body Composition
2025 · Coskun T, et al.
View SourcePubMed CentralTriple Agonism-Based Therapies for Obesity
Review · 2024
View SourceEli LillyGLP-3 RT TRIUMPH Phase 3 Trial Program
2025
View SourcePubChemGLP-3 RT Compound Information
View SourceClinicalTrials.govGLP-3 RT Clinical Trials Registry
View SourceProducts are intended solely for laboratory and scientific research purposes. Not intended for human consumption, veterinary use, diagnosis, treatment, cure, or prevention of disease.
All the research compounds you need, with the confidence that every batch is 8× tested before it ships.
Subscribe to our Newsletter
Subscribe to our newsletter to get daily insights, news, updates.